鵬翎股份(300375.SZ):公司控股股東、實控人將由張洪起變更為王志方
格隆匯 11 月 20日丨鵬翎股份(300375.SZ)公佈,2020年11月20日,公司收到通知,公司控股股東、實際控制人張洪起與王志方於2020年11月20日簽署了《合作框架協議》。張洪起擬將其持有的上市公司約2.13億股份(占上市公司總股本的29.89%,“標的股份”)轉讓給王志方,具體轉讓數量以雙方正式簽署的股份轉讓協議為準。同時,雙方同意張洪起擬將標的股份所對應的表決權在雙方約定的授權期限內不可撤銷地委託給王志方行使,有關表決權委託的具體事項以及雙方有關表決權委託的權利義務關係,由雙方另行簽訂協議加以明確約定。此次交易事項完成後,公司的控股股東、實際控制人將由張洪起變更為王志方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.